|Bid||20.86 x 1100|
|Ask||0.00 x 800|
|Day's Range||21.35 - 22.00|
|52 Week Range||14.40 - 22.74|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.80|
Amphastar Pharmaceuticals, Inc., (AMPH) announced today that Primatene® MIST has been launched. Primatene® MIST is an epinephrine inhalation aerosol bronchodilator suspension, which is the only FDA-approved metered dose inhaler (MDI) for asthma in the over-the-counter (OTC) market in the United States. Primatene® MIST is now available nationwide at Walgreens stores and online at Walgreens and CVS. The Company is currently building additional inventory to provide Primatene® MIST to more pharmacy chains and big box retail stores in the coming months.
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]
Jack Zhang became the CEO of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in 1996. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
Amphastar Pharmaceuticals (AMPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Investors are always looking for growth in small-cap stocks like Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), with a market cap of US$953m. However, an important fact which most ignore is: how financially Read More...
Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Bill Peters, CFO will be presenting at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 1:30 p.m. Eastern Time, New York, NY. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar (AMPH) delivered earnings and revenue surprises of 0.00% and 1.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Rancho Cucamonga, California-based company said it had profit of 5 cents per share. Earnings, adjusted for non-recurring costs, came to 12 cents per share. The results matched Wall Street expectations. ...
Reports Net Revenues of $75.5 Million for the Three Months Ended September 30, 2018 RANCHO CUCAMONGA, Calif., Nov. 08, 2018 -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH).
Amphastar Pharmaceuticals, Inc., (AMPH) announced today that the U.S. Food and Drug Administration (FDA) granted approval of its New Drug Application (NDA) for Primatene® MIST (epinephrine inhalation aerosol bronchodilator suspension), which is delivered by a metered dose inhaler (MDI) with a non-chlorofluorocarbon (CFC) propellant. Primatene® MIST is the only FDA-approved asthma inhaler available without a prescription in the United States.
Amphastar Pharmaceuticals, Inc. (AMPH) announced that the Company will release results for its Third quarter of 2018 ended September 30, 2018, after the market closes on Thursday, November 8, 2018, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 5587773.
Amphastar Pharmaceuticals, Inc. (AMPH) announced that the Company will release results for its Third quarter of 2018 ended September 30, 2018, after the market closes on Wednesday, November 8, 2018, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 5587773.
Every investor in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often Read More...